# Blood-based biomarker discovery in motor neuron disease using nucleic acid-linked immuno-sandwich assay.

- **DOI:** [10.1093/braincomms/fcag180](https://doi.org/10.1093/braincomms/fcag180)
- **Rating:** Limited (2.8 out of 5)
- **Verdict:** Serum NULISAseq reproduces established MND biomarker signals and cross-platform correlations, but unadjusted demographic confounding limits disease-specific interpretation.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1093%2Fbraincomms%2Ffcag180

## Key claims

1. Neurofilament light and heavy chain, total tau (t-tau), phosphorylated tau (pTau)-181, pTau-217, pTau-231, fatty acid binding protein 3, amyloid beta (Aβ) 38 and Aβ40 levels were significantly elevated in MND (P < 0.05).
   - Support: Supported
   - Type: Primary finding
   - Basis: cross-sectional unadjusted comparisons limit disease specificity, especially for low-detectability pTau-217
   - Location: Abstract; Results, Fig. 2A
2. Simoa and NULISAseq assays demonstrated strong correlations for NfL and GFAP (r > 0.90).
   - Support: Well-supported
   - Type: Secondary
   - Basis: reported Spearman correlations directly support the claim for both measured analytes
   - Location: Abstract; Results, Fig. 3A–B
3. Results add confidence in the validity and reproducibility of biomarkers identified using NULISAseq.
   - Support: Tentative
   - Type: Secondary
   - Basis: two-analyte cross-platform correlation cannot establish broader biomarker validity or reproducibility
   - Location: Abstract; Conclusion

## Strengths

- **Orthogonal comparison with established Simoa assays** NULISAseq and Simoa measurements were strongly correlated for NfL and GFAP, providing direct cross-platform evidence for those two analytes.
  - Dimension: contribution
  - Location: Results, Fig. 3A–B
- **Defined assay quality-control procedures** The workflow reports a randomized plate map, internal-control acceptance ranges, detectability thresholds, duplicate Simoa measurements, and a CV criterion.
  - Dimension: methodological rigour
  - Location: Methods, NULISAseq Profiling and Simoa sections
- **Direct engagement with recent literature** The discussion compares the serum findings with recent plasma and genetic-ALS NULISAseq studies and delineates the serum and broader-MND extensions.
  - Dimension: positioning
  - Location: Discussion, paragraphs 2–4

## Limitations

- **Primary comparisons lack confounding adjustment** Age and sex differed between disease and control groups, but biomarker comparisons used unadjusted independent t-tests without matching, regression, stratification, or sensitivity analysis.
  - Dimension: methodological rigour
  - Location: Methods, Statistical Analysis; Results, paragraphs 1–2; Discussion, limitations paragraph
- **Selected-sample analyses overstate discrimination** Clustering and ROC analyses were conducted in the discovery sample using the nine proteins selected as significant, without cross-validation or independent validation. This limits claims of clear separation, heterogeneity, and diagnostic performance.
  - Dimension: methodological rigour
  - Location: Results, Fig. 2B and Supplementary Fig. 9; Discussion, heatmap-analysis paragraph
- **Conclusions exceed the pilot evidence** The Conclusion invokes astrocytic degeneration, pathophysiological insight, and assay robustness although GFAP was unchanged and the study was a small, unadjusted cross-sectional pilot.
  - Dimension: reporting
  - Location: Discussion, neuroinflammation and limitations paragraphs; Conclusion

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted. One reported value does not reconcile, but the key claims do not rest on it.
  - Minor reporting notes (1):
    - Descriptive: "NULISAseq CNS Disease Panel analysis identified 119 proteins with detectability above 20%, as more than 20% of the samples displayed signals above the LOD. One hundred and five markers had detectability above 80%. Three proteins had detectability below 20%; therefore, were excluded in group comparison analyses: pleiotrophin, guanosine diphosphate dissociation inhibitor 1, beta-synuclein" (Results, detectability paragraph) vs "Serum samples were analysed using the commercially available NULISAseq CNS Disease Panel 120 kit" (Materials and Methods, NULISAseq profiling). The reported detectability categories contain 119 + 3 = 122 proteins, two more than the stated 120-target panel size, without establishing an error in any reported biomarker comparison. → Conclusion holds
- **Reporting and transparency:** Clean. No reporting or research-conduct concern was raised that warrants a grounded finding.
  - Ethics approval: declared · Preregistration: not stated · Data availability: declared · Code availability: declared
- **Reference integrity:** Clean
  - 33 references in manuscript
  - 33 of 33 checkable references found in an index
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
